J
J. Gomez-Reino
Researcher at University of South Florida
Publications - 14
Citations - 741
J. Gomez-Reino is an academic researcher from University of South Florida. The author has contributed to research in topics: Sarilumab & Rheumatoid arthritis. The author has an hindex of 6, co-authored 14 publications receiving 705 citations.
Papers
More filters
Journal ArticleDOI
FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries
Axel Finckh,D. Neto,J. Gomez-Reino,Florenzo Iannone,Elisabeth Lie,Helena Canhão,Karel Pavelka,Carl Turesson,Xavier Mariette,J.-E. Gottenberg,Merete Lund Hetland +10 more
TL;DR: The results of this large pooled RA population of mostly inadequate responders to anti-TNFs, suggest that ABA retention and response to ABA treatment are not influenced by csDMARDs cotherapy.
Journal ArticleDOI
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up
Roy Fleischmann,Mark C. Genovese,Yong Lin,Gregory St John,Désirée van der Heijde,Sheldon Wang,J. Gomez-Reino,José A. Maldonado-Cocco,Marina Stanislav,Alan Kivitz,Gerd R Burmester +10 more
TL;DR: The long-term safety profile of sarilumab, either in combination with csDMARDs or as monotherapy, remained stable and consistent with the anticipated profile of a molecule that inhibits IL6 signalling.
Journal ArticleDOI
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Mark C. Genovese,Désirée van der Heijde,Yong Lin,Gregory St John,Sheldon Wang,Hubert van Hoogstraten,J. Gomez-Reino,Alan Kivitz,José A. Maldonado-Cocco,Bruno Seriolo,Marina Stanislav,Gerd R Burmester +11 more
TL;DR: Clinical efficacy, including inhibition of radiographic progression, reduction in disease activity and improvement in physical function, was sustained with sarilumab + methotrexate over 5 years and safety appeared stable over the 5-year period.
Journal ArticleDOI
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.
Thomas Karonitsch,D. Aletaha,Maarten Boers,Stefano Bombardieri,B. Combe,Maxime Dougados,Paul Emery,David T. Felson,J. Gomez-Reino,E.C. Keystone,Tore K Kvien,E. Martin-Mola,Marco Matucci-Cerinic,Pamela Richards,P.L.C.M. van Riel,Jeffrey Siegel,Josef S. Smolen,Tuulikki Sokka,D. van der Heijde,R. van Vollenhoven,M. M. Ward,George Wells,A. Zink,Robert Landewé +23 more
TL;DR: The approach based on scientific evidence from the literature as well as on expert input provided sufficient information to derive recommendations on reporting disease activity in RA clinical trials.
Journal ArticleDOI
FRI0322 Positivity for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide is Associated with A Better Drug Retention of Abatacept: Data from A Paneuropean Analysis of RA Registries
J.-E. Gottenberg,D. Neto,J. Gomez-Reino,Florenzo Iannone,Elisabeth Lie,Helena Canhão,Karel Pavelka,Carl Turesson,Merete Lund Hetland,Xavier Mariette,Axel Finckh +10 more
TL;DR: It is demonstrated that positivity for RF and anti-CCP are associated with better ABA retention, and this association was consistently observed across the European registries contributing to this pooled analysis and confirms the results of 3 smaller studies.